Please provide your email address to receive an email when new articles are posted on . The introduction of additional neflamapimod in an open-label extension led to significant clinical improvements.

After her mom's diagnosis of Lewy body dementia, a Lincoln woman said she noticed there was a lack of culturally diverse support options in Nebraska. Now, she's working to raise awareness and be part ...

Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating ...

Please provide your email address to receive an email when new articles are posted on . In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association ...

She looked at me with tears in her eyes, and I said, “Isn’t it nice to love someone so much that saying goodbye is so hard?” Her face relaxed, as if through the disease she was able to grasp a moment ...

Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of ...

CervoMed Inc. has announced that it will present at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders in Vienna, Austria, from April 1-5, 2025.

Lewy body disease is the second most common neurodegenerative disease after Alzheimer's disease. A research group from Lund University has now shown that the disease can be detected before symptoms ...